Find Cabozantinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1140909-48-3, Cabozantinib malate, Cabozantinib (s)-malate, Cabometyx, Cabozantinib malate (xl184), Xl184
Molecular Formula
C32H30FN3O10
Molecular Weight
635.6  g/mol
InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
FDA UNII
DR7ST46X58

Cabozantinib
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.
1 2D Structure

Cabozantinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid
2.1.2 InChI
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
2.1.3 InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
2.1.4 Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O
2.1.5 Isomeric SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C([C@@H](C(=O)O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
DR7ST46X58
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bms 907351

2. Bms-907351

3. Bms907351

4. Cabozantinib

5. Cometriq

6. Xl 184

7. Xl-184

8. Xl184 Cpd

2.3.2 Depositor-Supplied Synonyms

1. 1140909-48-3

2. Cabozantinib Malate

3. Cabozantinib (s)-malate

4. Cabometyx

5. Cabozantinib Malate (xl184)

6. Xl184

7. Cabozantinib (s-malate)

8. Cometriq

9. Cabozantinib S-malate [usan]

10. Dr7st46x58

11. Bms907351

12. Chebi:72319

13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

14. Cabometyx (tn)

15. Cometriq (tn)

16. Cabozantinib Malate (jan)

17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid

18. Cabozantinib S-malate (usan)

19. Cabozantinib Malate [jan]

20. Unii-dr7st46x58

21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

23. Xl184 Malate

24. Cabozantinib L-malate

25. Bms907351 Malate

26. Xl184(cabozantinib Malate)

27. Mls006010951

28. Chembl2103868

29. Dtxsid60915949

30. Ex-a2819

31. Mfcd20923480

32. S4001

33. 1140909-48-3 (malate)

34. Akos025401945

35. Cabozantinib S-malate [who-dd]

36. Ccg-270301

37. Cs-0201

38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor

39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

40. Ac-27471

41. As-75255

42. Hy-12044

43. Smr004702755

44. Cabozantinib S-malate [orange Book]

45. Sw218093-2

46. D10095

47. Q27139901

48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)

52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt

53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)

54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate

2.4 Create Date
2008-12-22
3 Chemical and Physical Properties
Molecular Weight 635.6 g/mol
Molecular Formula C32H30FN3O10
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count12
Rotatable Bond Count11
Exact Mass635.19152232 g/mol
Monoisotopic Mass635.19152232 g/mol
Topological Polar Surface Area194 Ų
Heavy Atom Count46
Formal Charge0
Complexity924
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

* Renal Cell Carcinoma (RCC):

Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):

- in treatment-nave adults with intermediate or poor risk,

- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

* Hepatocellular Carcinoma (HCC):

Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EX07


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694629800,"product":"CABOZANTINIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"0.33","actualQuantity":"0.33","unit":"KGS","unitRateFc":"12000","totalValueFC":"3830.9","currency":"USD","unitRateINR":963636.36363636365,"date":"14-Sep-2023","totalValueINR":"318000","totalValueInUsd":"3830.9","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"3919696","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694629800,"product":"CABOZANTINIB (S)-MALATE (FORM-S)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC","customerCountry":"CANADA","quantity":"0.75","actualQuantity":"0.75","unit":"KGS","unitRateFc":"35000","totalValueFC":"25997.4","currency":"USD","unitRateINR":2877333.3333333335,"date":"14-Sep-2023","totalValueINR":"2158000","totalValueInUsd":"25997.4","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"3927575","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710095400,"product":"CABOZANTINIB (S)-MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MALTA","customer":"PHARMACARE PREMIUM LTD","customerCountry":"MALTA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"20000","totalValueFC":"5646.8","currency":"USD","unitRateINR":1562956.6666666667,"date":"11-Mar-2024","totalValueINR":"468887","totalValueInUsd":"5646.8","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"8222802","productDescription":"API","marketType":"REGULATED MARKET","country":"MALTA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725042600,"product":"CABOZANTINIB (S) MALATE (OTHER)(TAX INV#MH2411600257 DT: 31.08.2024)","address":"407\/408,SHARDA CHAMBERS,","city":"MUMBAI, MAHARASHTRA.","supplier":"BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MALTA","customer":"PHRPELTD","customerCountry":"MALTA","quantity":"3.50","actualQuantity":"3.5","unit":"KGS","unitRateFc":"12500","totalValueFC":"43161.1","currency":"USD","unitRateINR":1034369.6799999999,"date":"31-Aug-2024","totalValueINR":"3620293.88","totalValueInUsd":"43161.1","indian_port":"Bombay Air","hs_no":"29332990","bill_no":"3661783","productDescription":"API","marketType":"REGULATED MARKET","country":"MALTA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"407\/408,SHARDA CHAMBERS,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1727721000,"product":"CABOZANTINIB (S)-MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY CO DUBAI LLC","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"14850","totalValueFC":"21909.7","currency":"USD","unitRateINR":1227333.3333333333,"date":"01-Oct-2024","totalValueINR":"1841000","totalValueInUsd":"21909.7","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"4486806","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736965800,"product":"CABOZANTINIB MALATE IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"NOBEL ILAC SANAYII VE TICARET AS","customerCountry":"TURKEY","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"12000","totalValueFC":"2855.1","currency":"USD","unitRateINR":984771.83999999997,"date":"16-Jan-2025","totalValueINR":"246192.96","totalValueInUsd":"2855.1","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"7318140","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1749580200,"product":"CABOZANTINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"REYKJAVIK KEFLAVIK","customer":"CORIPHARMA","customerCountry":"ICELAND","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"21000","totalValueFC":"10239.2","currency":"USD","unitRateINR":1759617.0600000001,"date":"11-Jun-2025","totalValueINR":"879808.53","totalValueInUsd":"10239.2","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"2619643","productDescription":"API","marketType":"REGULATED MARKET","country":"ICELAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
14-Sep-2023
11-Jun-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

INTERMEDIATE SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 35654-56-9

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...

Tagoor Laboratories

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 849217-48-7

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...

Tagoor Laboratories

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 190728-25-7

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...

Tagoor Laboratories

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 113020-21-6

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...

Tagoor Laboratories

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 598-10-7

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...

Tagoor Laboratories

06

BIO Asia-Taiwan
Not Confirmed
arrow
BIO Asia-Taiwan
Not Confirmed
arrow

CAS Number : 35654-56-9

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

07

BIO Asia-Taiwan
Not Confirmed
arrow
BIO Asia-Taiwan
Not Confirmed
arrow

CAS Number : 598-10-7

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

08

BIO Asia-Taiwan
Not Confirmed
arrow
BIO Asia-Taiwan
Not Confirmed
arrow

CAS Number : 849217-48-7

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

09

BIO Asia-Taiwan
Not Confirmed
arrow
BIO Asia-Taiwan
Not Confirmed
arrow

CAS Number : 190728-25-7

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

10

BIO Asia-Taiwan
Not Confirmed
arrow
BIO Asia-Taiwan
Not Confirmed
arrow

CAS Number : 35654-56-9

End Use API : Cabozantinib

About The Company : We are into manufacturing of bulk drug Intermediates and Active Pharmaceutical Ingredients (API). Our core competence is contract manufacturing for our clients ...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - EQ 20MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

DOSAGE - CAPSULE;ORAL - EQ 80MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Direct Compression

read-more
read-more

Granulation

read-more
read-more

Lubricants & Glidants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Empty Capsules

read-more
read-more

Co-Processed Excipients

read-more
read-more

Coloring Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Taste Masking

read-more
read-more

Topical

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

France
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 349

2019 Revenue in Millions : 293

Growth (%) : 19

blank

02

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

France
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 390

2020 Revenue in Millions : 349

Growth (%) : 23

blank

03

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

France
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 481

2021 Revenue in Millions : 390

Growth (%) : 23

blank

04

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

Japan
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 59

2021 Revenue in Millions : 54

Growth (%) : 10

blank

05

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

France
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 577

2022 Revenue in Millions : 481

Growth (%) : 19

blank

06

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

Japan
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 56

2022 Revenue in Millions : 60

Growth (%) : 5

blank

07

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

France
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 617

2023 Revenue in Millions : 577

Growth (%) : 7

blank

08

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

Japan
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 58

2023 Revenue in Millions : 56

Growth (%) : 4

blank

09

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

France
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 7

2015 Revenue in Millions : Not Reported

Growth (%) : New Launch

blank

10

Brand Name : Cabometyx

Cabozantinib

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Cabometyx

France
arrow
BIO Asia-Taiwan
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 64

2016 Revenue in Millions : 9

Growth (%) : 618

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 1140909-48-3 / Cabozantinib API manufacturers, exporters & distributors?

Cabozantinib manufacturers, exporters & distributors 1

82

PharmaCompass offers a list of Cabozantinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cabozantinib manufacturer or Cabozantinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cabozantinib manufacturer or Cabozantinib supplier.

PharmaCompass also assists you with knowing the Cabozantinib API Price utilized in the formulation of products. Cabozantinib API Price is not always fixed or binding as the Cabozantinib Price is obtained through a variety of data sources. The Cabozantinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Cabozantinib

Synonyms

1140909-48-3, Cabozantinib malate, Cabozantinib (s)-malate, Cabometyx, Cabozantinib malate (xl184), Xl184

Cas Number

1140909-48-3

Unique Ingredient Identifier (UNII)

DR7ST46X58

About Cabozantinib

Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

Cabozantinib L-Malate Salt Manufacturers

A Cabozantinib L-Malate Salt manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabozantinib L-Malate Salt, including repackagers and relabelers. The FDA regulates Cabozantinib L-Malate Salt manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabozantinib L-Malate Salt API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Cabozantinib L-Malate Salt manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Cabozantinib L-Malate Salt Suppliers

A Cabozantinib L-Malate Salt supplier is an individual or a company that provides Cabozantinib L-Malate Salt active pharmaceutical ingredient (API) or Cabozantinib L-Malate Salt finished formulations upon request. The Cabozantinib L-Malate Salt suppliers may include Cabozantinib L-Malate Salt API manufacturers, exporters, distributors and traders.

click here to find a list of Cabozantinib L-Malate Salt suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cabozantinib L-Malate Salt USDMF

A Cabozantinib L-Malate Salt DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabozantinib L-Malate Salt active pharmaceutical ingredient (API) in detail. Different forms of Cabozantinib L-Malate Salt DMFs exist exist since differing nations have different regulations, such as Cabozantinib L-Malate Salt USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Cabozantinib L-Malate Salt DMF submitted to regulatory agencies in the US is known as a USDMF. Cabozantinib L-Malate Salt USDMF includes data on Cabozantinib L-Malate Salt's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabozantinib L-Malate Salt USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Cabozantinib L-Malate Salt suppliers with USDMF on PharmaCompass.

Cabozantinib L-Malate Salt KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Cabozantinib L-Malate Salt Drug Master File in Korea (Cabozantinib L-Malate Salt KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabozantinib L-Malate Salt. The MFDS reviews the Cabozantinib L-Malate Salt KDMF as part of the drug registration process and uses the information provided in the Cabozantinib L-Malate Salt KDMF to evaluate the safety and efficacy of the drug.

After submitting a Cabozantinib L-Malate Salt KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabozantinib L-Malate Salt API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Cabozantinib L-Malate Salt suppliers with KDMF on PharmaCompass.

Cabozantinib L-Malate Salt WC

A Cabozantinib L-Malate Salt written confirmation (Cabozantinib L-Malate Salt WC) is an official document issued by a regulatory agency to a Cabozantinib L-Malate Salt manufacturer, verifying that the manufacturing facility of a Cabozantinib L-Malate Salt active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cabozantinib L-Malate Salt APIs or Cabozantinib L-Malate Salt finished pharmaceutical products to another nation, regulatory agencies frequently require a Cabozantinib L-Malate Salt WC (written confirmation) as part of the regulatory process.

click here to find a list of Cabozantinib L-Malate Salt suppliers with Written Confirmation (WC) on PharmaCompass.

Cabozantinib L-Malate Salt NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabozantinib L-Malate Salt as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Cabozantinib L-Malate Salt API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Cabozantinib L-Malate Salt as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Cabozantinib L-Malate Salt and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabozantinib L-Malate Salt NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Cabozantinib L-Malate Salt suppliers with NDC on PharmaCompass.

Cabozantinib L-Malate Salt GMP

Cabozantinib L-Malate Salt Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cabozantinib L-Malate Salt GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabozantinib L-Malate Salt GMP manufacturer or Cabozantinib L-Malate Salt GMP API supplier for your needs.

Cabozantinib L-Malate Salt CoA

A Cabozantinib L-Malate Salt CoA (Certificate of Analysis) is a formal document that attests to Cabozantinib L-Malate Salt's compliance with Cabozantinib L-Malate Salt specifications and serves as a tool for batch-level quality control.

Cabozantinib L-Malate Salt CoA mostly includes findings from lab analyses of a specific batch. For each Cabozantinib L-Malate Salt CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cabozantinib L-Malate Salt may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabozantinib L-Malate Salt EP), Cabozantinib L-Malate Salt JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabozantinib L-Malate Salt USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty